Wondershare UniConverter12 Released: A Complete Video Toolbox - Become More Powerful
31.8.2020 11:15:00 EEST | Business Wire | Press release
While working with videos, several editing and other functions are needed like conversion, downloading, recording, cutting, cropping, editing metadata, compression, and others. To get all these tasks done like pro several editing software are available and one such professional tool is Wondershare UniConverter . Formerly known as Wondershare Video Converter Ultimate, the latest version, UniConverter v12, hit the market on July 08, 2020. The latest version claims to offer drastically improved performance of the “Video Converter” tool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005217/en/
Wondershare UniConverter Version 12 (Photo: Business Wire)
Part 1: Key features of Wondershare UniConverter software
1. Video Conversion: With the availability of different video formats and devices, conversion becomes an essential requirement that Wondershare UniConverter software can easily take care of. With support to over 1000 formats and devices, you will not face any playback issues with your video files as they can be quickly converted to the desired format.
Video conversion takes place without any quality loss and there is also an option to merge multiple files.
2. Edit Video: Video customization is important to enhance your overall video and make it look presentable. Wonderware comes loaded with a complete built-in editor that supports all required tools like cutting, cropping, adding watermark, adding special effects, and more.
3. Burn video to DVD: To create a physical backup and to play your digital files on a DVD player, the software supports the function where your video files can be quickly converted into a DVD.
4. Compress Video Size: When you are finding it difficult to accommodate your video files, compression comes to the rescue. Using Wondershare UniConverter video files in almost all formats can be quickly resized and compressed without losing any quality.
5. Downloading and recording: For offline playback of your videos on an array of devices, the software allows video downloads from over 10,000 sites including popular names like DailyMotion, YouTube, Vimeo, and more.
6. Other Features: Several other features are also supported by the software like fixing metadata, VR conversion, GIF-making and more.
Part 2: Some of the mention-worthy advancements that Wondershare promises the users will get with UniConverter v12 include:
- Designed using the industry leading APEXTRANS technology exclusive to Wondershare, the updated app is said to convert or compress the videos with zero picture quality deterioration. If the claims are correct, in contrast to its predecessor, the improved GPU acceleration exploits the multicore processor to its maximum.
- The program allows lossless batch conversions where setting global output parameters, and multiple videos can be converted to a relevant format in a single go with absolutely no quality loss.
- Otherwise, the app can convert 4K and 8K videos and can perform batch conversion for those large files.
- HEVC is another format type that UniConverter v12 supports and claims to convert the videos with no loss of picture quality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005217/en/
Contact information
Name: Tyler Jäger
Email: pr@wondershare.de
Address: Vancouver, Canada
Phone number: +86 755 86665000
Website:
Germany: https://uniconverter.wondershare.de/
France: https://uniconverter.wondershare.fr/
Italy: https://uniconverter.wondershare.it/
Spain: https://uniconverter.wondershare.es/
Netherlands: https://videoconverter.wondershare.com/nl/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom